CMS Belgium assisted Celyad SA, a Belgian clinical-stage biopharmaceutical company listed on Nasdaq, Euronext Brussels and Euronext Paris, in connection with its successful EUR 46.1 million global equity offering.
Celyad raised EUR 46.1 million (including 15% greenshoe option) in a global SEC-registered equity global offering targeting institutional investors across the US and Europe in a concurrent placement of American Depositary Shares (ADSs) offered in the United States, Canada and certain countries outside of Europe, as well as ordinary shares in Europe.
The CMS team that assisted Celyad included Vincent Dirckx, Corporate and Finance Partner in CMS Belgium’s Corporate Department, and Adrien Lanotte, Senior Associate specialised in capital market transactions.
